- Active Pharmaceutical Ingredients
- Varenicline tartrate
- Aprepitant, Fosapitant Intermediates
- Fosaprepitant Dimeglumine
- Vildagliptin
- Efinaconazole
- Luliconazole Intermediate
- Gadoterate Meglumine
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- Varenicline tartrate
- Aprepitant 287930-73-8
- Aprepitant 127852-28-2
- Aprepitant 287930-75-0
- Aprepitant 200000-59-5
- Aprepitant 155742-64-6
- Aprepitant 252742-72-6
- Fosaprepitant Dimeglumine 990-91-0
- Fosaprepitant Dimeglumine 265121-01-5
- Vildagliptin 207557-35-5
- Vildagliptin 702-82-9
- Efinaconazole 144230-50-2
- Efinaconazole 133775-25-4
- Efinaconazole 127000-90-2
- Gadoterate Meglumine
- Mirabegron
- Luliconazole 98873-55-3
- Luliconazole 126534-31-4
- Atazanavir sulfate
- Bortezomib 179324-87-9
- Bortezomib 114457-94-2
- Bortezomib 205393-22-2
- Brinzolamide
- Rivaroxaban Intermediate 446292-08-6
- Rivaroxaban Intermediate 446292-07-5
- Cinacalcet Hydrochloride 1005450-55-4
- Cinacalcet Hydrochloride 585-50-2
- Eletriptan Intermediate
- Indacaterol intermediate 312753-53-0
- Indacaterol intermediate 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Diabetes medication Linagliptin 668270-12-0
【Catalog number】AP4700
【CAS #】668270-12-0
【Molecular formula】C16H20F6N5O6P
【Product Brief】US-DMF No. 29692 Lilaliptin, English name Linagliptin, American Chemical Abstracts registration number cas 668270-12-0.
Linagliptin
CAS 668270-12-0
US-DMF No. 29692
Alias 8-[(3R) -3-amino-1-piperidinyl] -7- (2-butynyl) -3,7-dihydro-3-methyl-1-[(4-methyl- 2-quinazolinyl) methyl] -1H-purine-2,6-dione
Catalog number AP4700
CAS # 668270-12-0
Molecular formula C25H28N8O2
Molecular weight 472.54
Structural formula
Product introduction
CAS 668270-12-0
US-DMF No. 29692 Lilaliptin, English name Linagliptin, American Chemical Abstracts registration number cas 668270-12-0.
Lillaritin (cas 668270-12-0) was approved by the FDA on May 2, 2011 to improve dietary and exercise control of blood glucose levels in people with type 2 diabetes. Lilaridine improves patients' glycemic control by inhibiting dipeptidyl peptidase-4 (DPP-4).
VIWIT 沪ICP备12014533号-1